[Biomarkers of Alzheimer's disease].
Recent researches of CSF biomarkers, such as combinations of tau, A beta40, A beta42, are now establishing clinical evidence. These specific biomarkers should be used in clinical practice. To detect incipient AD form MCI and very early AD, these CSF biomarkers are quite useful. Newly developing biomarkers, such as phosphorylated tau and plasma A beta, must be established by large scale prospective study and autopsy-correlations. Thus, the contribution of these biomarkers is desired for diagnosis and clinical practice for Alzheimer's disease.
Shoji
Mikio
M
Department of Neurology, Neuroscience, Biophysiological Science, Okayama University Graduate School of Medicine and Dentistry.
D000544:Alzheimer Disease / Q000175:diagnosis*; D015415:Biomarkers / Q000032:analysis*; D006801:Humans
D015415:Biomarkers